Fig. 7

CD36⁺CD8⁺ T cells predict poor therapeutic response to chemotherapy. A, B, D. NSCLC patients with low infiltration of CD36⁺CD8⁺ T cells at early stages showed no significant difference in chemotherapy response and prognosis compared to patients with high infiltration of CD36⁺CD8⁺ T cells. C, E, F. Patients with high infiltration of CD36⁺CD8⁺ T cells at advanced stages showed significant difference in chemotherapy response and prognosis compared to patients with low infiltration of CD36⁺CD8⁺ T cells. G. Level changes of GZMB⁺, IFN-γ⁺, PD-1⁺ and TIGIT⁺ CD8⁺ T cells from patients (n = 14) after SSO or DMSO treatment. ns: no significance, *p < 0.05 by paired t test